HBL - Hadasit Bio-Holdings Ltd Stock price

Equities

HDST-M

IL0010954050

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 10:24:36 2023-11-30 am EST Intraday chart for HBL - Hadasit Bio-Holdings Ltd 5-day change 1st Jan Change
54.30 ILa -10.54% -10.54% -58.10%

Financials

Sales 2022 * - Sales 2023 * - Capitalization 14.37 M 3.88 M 1,437 M
Net income 2022 -31.00 M -8.36 M -3,100 M Net income 2023 * - EV / Sales 2022
-
Net cash position 2022 12.93 M 3.49 M 1,293 M Net cash position 2023 * - 0 0 EV / Sales 2023 * -
P/E ratio 2022
-0,46x
P/E ratio 2023 *
Employees 2
Yield 2022
-
Yield 2023 *
-
Free-Float 25.00%
More Fundamentals * Assessed data
Dynamic Chart
1 day-10.54%
1 week-10.54%
1 month-20.50%
3 months-39.19%
6 months-61.32%
Current year-58.10%
More quotes
1 week
48.40
Extreme 48.4
48.40
1 month
48.40
Extreme 48.4
63.70
Current year
40.10
Extreme 40.1
210.00
1 year
40.10
Extreme 40.1
210.00
3 years
40.10
Extreme 40.1
1 153.00
5 years
40.10
Extreme 40.1
1 180.00
10 years
40.10
Extreme 40.1
1 430.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 2015
Chairman 60 2014
Comptroller/Controller/Auditor 53 2015
Members of the board TitleAgeSince
Director/Board Member 68 2018
Director/Board Member 66 2016
Director/Board Member 52 2017
More insiders
Date Price Change Volume

Delayed Quote TEL AVIV STOCK EXCHANGE, November 30, 2023 at 10:24 am EST

More quotes
HBL Hadasit Bio Holdings Ltd (Hadasit) is an investment company, a subsidiary of Hadassah Medical Organization (HMO). The Company's subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The Company together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Company's framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.
More about the company
  1. Stock
  2. Equities
  3. Stock HBL - Hadasit Bio-Holdings Ltd - TEL AVIV STOCK EXCHANGE
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer